Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Cash & Equivalents (2023 - 2025)

Profound Medical (PROF) has 3 years of Cash & Equivalents data on record, last reported at $59.7 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 8.76% year-over-year to $59.7 million; the TTM value through Dec 2025 reached $59.7 million, up 8.76%, while the annual FY2025 figure was $59.7 million, 8.76% up from the prior year.
  • Cash & Equivalents reached $59.7 million in Q4 2025 per PROF's latest filing, up from $24.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $59.7 million in Q4 2025 and bottomed at $24.8 million in Q3 2025.
  • Average Cash & Equivalents over 3 years is $41.2 million, with a median of $40.8 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: surged 109.48% in 2024, then grew 8.76% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $26.2 million in 2023, then skyrocketed by 109.48% to $54.9 million in 2024, then rose by 8.76% to $59.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $59.7 million in Q4 2025, $24.8 million in Q3 2025, and $35.2 million in Q2 2025.